Equine squamous gastric disease (ESGD) often necessitates extended administration of acid-suppressing drugs, prompting growing interest in nutraceuticals with potential anti-ulcer effects. This investigation evaluates the therapeutic impact of the Trophogast pellet on ESGD in endurance horses. Fifteen endurance horses were enrolled following gastroscopic assessment and were randomly allocated either to a treatment cohort, which received a Trophogast pellet for 30 days along with management adjustments, or to a control cohort, which only underwent management revisions. Gastroscopy was repeated at the end of the intervention. Lesions were graded according to the Equine Gastric Ulcer Council scoring criteria. Each horse was weighed at baseline and at completion. Pre- and post-treatment ESGD scores and bodyweight values were analysed. At baseline, the treatment group exhibited a median ESGD grade of 2, whereas the control horses showed a median grade of 1. Following the 30-day period, the treatment cohort demonstrated a significant reduction in ESGD severity (median 1, p = 0.0078), while the control cohort showed no variation (median 2). Bodyweight remained unchanged in both groups. Trophogast pellet supported improvement of mild ESGD in horses undergoing endurance training.
